Research Information System
ANIMALS, vol.12, no.440, pp.1-14, 2022 (Journal Indexed in SCI Expanded)
Abstract: MMVD, the most common cause of CHF in dogs, is a chronic disease with variable
clinical signs, with some patients remaining asymptomatic while others develop CHF. Here, we
aimed to evaluate serum proteins by proteomic analysis in dogs at different stages of CHF due to
MMVD, and proteome behaviors after conventional treatment. A total of 32 dogs were divided
equally into four groups—stage A (healthy/controls), stage B2 (asymptomatic), stage C and stage
D (symptomatic)—according to the ACVIM consensus. Serum proteomes were evaluated using
LC/MS-based label-free differential proteome analysis. The study revealed 157 different proteins;
11 were up- and 21 down-regulated in dogs with CHF compared to controls. In stage B2 dogs,angiotensinogen (AGT) was up-regulated, but immunoglobulin iota chain-like, lipopolysaccharidebinding
protein, and carboxypeptidase (CPN) were down-regulated. In stage C dogs, complement
C3 (C3) and inter-alpha-trypsin inhibitor heavy chain were up-regulated, but hemopexin, and actincytoplasmic-
1 (ACT-1) were down-regulated. In stage D dogs, AGT was up-regulated, whereas
tetranectin, paraoxonase-1, adiponectin and ACT-1 were down-regulated. A decrease in CPN, C3
and AGT and an increase in ACT-1 were observed after treatment of dogs in stage C. This pilot study
identified that dogs at different stages of CHF show different serum protein composition which has
potential to be biomarker for diagnose and treatment monitorization.
Keywords: proteomic; mitral valve disease; heart disease; ACVIM; dogs